Connect with us

News Wire

Octapharma AG: Final data from the NuProtect study published on the immunogenicity of Nuwiq® in previously untreated patients with severe haemophilia A

LACHEN, Switzerland, Feb. 22, 2021 /PRNewswire/ — Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. “Simoctocog Alfa (Nuwiq®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study” https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623). 

Octapharma Logo

The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq®. The study recruited patients of any age and ethnicity at 38 sites in 17 countries and followed patients for 100 exposure days or up to 5 years. With enrolment of 110 patients, the NuProtect study was the largest clinical study to investigate a single product in true PUPs.

Of 105 evaluable PUPs with severe haemophilia A who received Nuwiq® for the prevention and treatment of bleeding:

  • 16.2% (17/105) of patients developed high-titre inhibitors
  • 10.5% (11/105) of patients developed low-titre inhibitors, five of which were transient
  • 26.7% (28/105) of patients developed any inhibitor

“The NuProtect study showed that there was a low risk of inhibitor development in PUPs starting treatment with Nuwiq®,” commented Dr Ri Liesner, coordinating investigator of the NuProtect study and clinician at Great Ormond Street Hospital for Children in London, UK. “These data indicate Nuwiq® may be an attractive option for people newly diagnosed with severe haemophilia A, who are young children and represent a vulnerable patient subset.”

The development of inhibitors to replacement factor VIII (FVIII) is a concern for doctors, as well as for patients and their families, particularly when first starting treatment. Inhibitors render FVIII therapy ineffective and limit treatment options.

These data complement the wealth of clinical experience in patients with haemophilia A receiving Nuwiq® for the treatment and prevention of bleeding.

“Nuwiq® was developed in a human cell line with the aim of minimising inhibitor risk in PUPs,” said Larisa Belyanskaya, Head of Octapharma’s IBU Haematology. “We are pleased to be able to share these positive data, which reflect this aim and which we hope will contribute to addressing this key treatment challenge.”

“We know that haemophilia A patients face a lifetime of treatment decisions,” commented Olaf Walter, Board Member at Octapharma. “These data highlight the potential of Nuwiq® to reassure PUPs and their families as they start their treatment. This publication brings us closer to Octapharma’s goal of enabling all patients to lead healthy lives.”

Earlier this year the FDA approved the inclusion of the immunogenicity data from the NuProtect study in the Nuwiq® Prescribing Information. Further publications on other analyses from the NuProtect study are planned.

Professor Anthony Chan, a co-author of the publication and Professor of Paediatrics at McMaster University, Canada, said: “Congratulations and thanks to Octapharma for developing Nuwiq, sponsoring the trial and providing a very good therapy for patients with haemophilia A.“

Octapharma would also like to extend thanks to all participating centres, as well as patients and their caregivers, for their contribution to the study.

About Nuwiq®

Nuwiq® (simoctocog alfa) is a 4th generation recombinant factor VIII (rFVIII) protein, produced in a human cell line without chemical modification or fusion with any other protein1. It is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for von Willebrand factor1. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 previously treated patients (PTPs; 190 individuals) with severe haemophilia A, including 59 children1. Nuwiq® is available in 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, 3000 IU and 4000 IU presentations2. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency) across all age groups2.

1.  Lissitchkov T et al. Ther Adv Hematol 2019; 10:2040620719858471.

2.  Nuwiq® Summary of Product Characteristics.

About Haemophilia A

Haemophilia A is an X-linked hereditary bleeding disorder caused by a deficiency of factor VIII (FVIII) which, if left untreated, may lead to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. The disorder affects around one in every 10,000 males worldwide. Prophylaxis with replacement FVIII therapy reduces the number of bleeding episodes and the risk of permanent joint damage. 

About Octapharma

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.

Octapharma employs more than 9,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Haematology, Immunotherapy, and Critical Care.

Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, and operates more than 160 plasma donation centres across Europe and the USA.

Logo: https://mma.prnewswire.com/media/1442016/Octapharma_Logo.jpg  

 

 

Related Topics:
Continue Reading
Advertisement
Click to comment

You must be logged in to post a comment Login

Leave a Reply

News Wire

Harper Collins Publishers India is Delighted to Announce the Recent Publication of ‘People We Love’ by Preeti Shenoy

NEW DELHI, June 19, 2026 /PRNewswire/ — HarperCollins Publishers India is delighted to share the recent publication of People We Love by bestselling author Preeti Shenoy. At once tender and sharp, this collection of stories offers intimate, truthful and relatable portraits of the people we cherish, the ones we lose, and the people we become.

ABOUT THE BOOK

The people we love never truly leave our story…

In these tender yet piercing stories, Preeti Shenoy returns to some of her most beloved characters to reveal who they were before they appeared in her bestselling novels It’s All in the Planets and The One You Cannot Have.

Aniket, a coder, carries the weight of a longing for Trisha that he cannot bring himself to act on. Nidhi abandons her corporate life to teach pottery, only to discover that clay is far more forgiving than the people she loves. A quiz competition sparks an unlikely romance between Aman and Shruti, one that must withstand parental disapproval and class divides. And Anjali, a journalist, is so busy chasing stories that she almost misses the one unfolding in her own life.

Set against the pulse of contemporary India, People We Love explores the tug-of-war between duty and desire, family and freedom, who we are and who we dare to be. Intimate and deeply felt, these are stories about love that stays, leaves and almost slips away … love that quietly and irrevocably shapes the people we become.

Preeti Shenoy, author, says, “People We Love is a collection of three long stories, prequels to my bestsellers It’s All in the Planets and The One You Cannot Have. If you have read those books, you already know how these characters’ stories unfold. But what you don’t know yet is where it all began, the loves they carried, the choices they made, and the people they were before life shaped them into who you met on those pages. Writing these prequels felt like returning to a home I hadn’t realised I missed, and discovering rooms I had never been in before.”

Rashmi Menon, Associate Publisher – HarperCollins India, adds, “Preeti Shenoy has an extraordinary gift for finding the heartbeat of ordinary lives. People We Love is a warm, wise and deeply humane collection of short stories that reunites readers with favourite characters from her bestselling novels It’s All in the Planets and The One You Cannot Have, weaving them into fresh, deeply satisfying narratives. These characters feel like people you know, and their journeys will move, comfort and surprise you. This uplifting, thought–provoking collection reminds us why we turn to stories in the first place. We couldn’t be more excited to share it with our readers.”

ABOUT THE AUTHOR 

Preeti Shenoy is among the highest-selling authors in India. She was featured on the Forbes longlist of the most influential celebrities in India. Her books include When Love Came Calling, Wake Up Life, Is Calling, Life Is What You Make It, The Rule Breakers, A Hundred Little Flames, It’s All in the Planets, Why We Love the Way We Do, The Secret Wish List, The One You Cannot Have and many others. Her work has been translated into many Indian languages. Preeti is also a motivational speaker, an avid fitness enthusiast, and an artist specializing in portraiture and illustrated journalling. Preeti lives in Bengaluru, Karnataka.

ABOUT HARPERCOLLINS PUBLISHERS INDIA

At HarperCollins Publishers India, we believe in telling the best stories and ensuring they reach the widest readership. We publish around 250 new books every year across 10 imprints, adding to a diverse catalogue of more than 3,000 titles in print and digital formats, with an array of genres and voices that ensure there is a book for every reader. Our authors have won some of the most prestigious literary awards, and we are proud to publish many acclaimed writers, alongside new and emerging voices shaping contemporary literature. We are also the publishers of The White Tiger by Aravind Adiga, winner of the Booker Prize 2008, and Girl in White Cotton by Avni Doshi, shortlisted for the Booker Prize in 2020, and HarperCollins India itself has been awarded “Publisher of the Year” several times. In addition, we represent some of the finest global publishers such as Harvard University Press, Lonely Planet, Oneworld, Nosy Crow, Usborne, and National Geographic Children, bringing Indian readers access to world-class books and ideas. We are also proud to be certified as a Great Place to Work for two consecutive years, a recognition of our culture, people, and values that make HarperCollins India a truly inspiring workplace. 

PRESS CONTACT:

Nandini Tripathi, Manager – Marketing (Commercial)

Email: nandini.tripathi@harpercollins.co.in | Mobile: +91 9718928839

Photo: https://oyefilmy.com/wp-content/uploads/2026/06/harper-collins-publishers-india-is-delighted-to-announce-the-recent-publication-of-people-we-love-by-preeti-shenoy-1.jpg

Logo: https://mma.prnewswire.com/media/2105077/4665143/HarperCollins_Logo.jpg

 

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/harper-collins-publishers-india-is-delighted-to-announce-the-recent-publication-of-people-we-love-by-preeti-shenoy-302805348.html

Continue Reading

News Wire

Fulfilling PM Modi’s Dream of Atmanirbhar Bharat: India’s AI Writing Startup Kreativespace Incubated at IIT Kharagpur

  1. Kreativespace, an Indian AI-powered writing platform founded by Vinet Kakadea, has been incubated at IIT Kharagpur and recognized by SVNIT University, Ministry of Education under Bodhan AI Conclave also through the NVIDIA Inception Program, AWS Startup Program, and DPIIT under Startup India.
  2. The platform unifies 8 AI-powered writing tools, along with AI Humanizer and Message AI feature being the latest addition into a single ecosystem, so you can generate and refine content all in one place.
  3. The company reports more than 50,000+ signed-up users, 75,000+ anonymous users, and roughly 100,000 monthly website visitors, positioning itself as the only Indian company operating at scale in the global AI writing market.

SURAT, India, June 19, 2026 /PRNewswire/ — Kreativespace, an AI-powered writing platform, is building out its position as the only homegrown alternative in a market long dominated by international tools such as Grammarly and QuillBot. Founded by Vinet Kakadea and incubated at IIT Kharagpur, the company has aligned its growth with the broader push behind Prime Minister Narendra Modi’s Atmanirbhar Bharat (Self-Reliant India) initiative, which encourages indigenous technology development capable of competing on a global scale.

Kreativespace Incubated at IIT Kharagpur

As AI adoption accelerates across India’s education, research, and enterprise sectors, Kreativespace is among a small group of Indian startups building writing technology designed to compete directly with established international platforms.

Kreativespace’s progress has been recognized by several institutions central to India’s startup and technology ecosystem. The company has been incubated at IIT Kharagpur, selected under SSIP 2.0 through SVNIT University, and chosen by the Ministry of Education to present its work at the Bodhan AI Conclave. It has also been accepted into the NVIDIA Inception Program and the AWS Startup Program, and holds DPIIT recognition under the Startup India initiative.

Where many writing-tool users rely on separate subscriptions for content generation to refinement for grammar correction, paraphrasing, plagiarism checking, citation generation, and editing, Kreativespace brings these functions into a single platform as a super-app for AI writing tools. The company says its approach centers on affordability and accessibility alongside performance, aiming to make advanced AI writing assistance available to a wider range of users regardless of geography or budget.

The idea for Kreativespace took shape while founder Vinet Kakadea was studying at New York University and Marymount University in the United States, where he experienced firsthand how students, researchers, and professionals often need multiple paid subscriptions to cover writing-related tasks. That fragmented experience led him to build a super-app offering each of these capabilities together, at a more accessible price point.

Kreativespace combines 8 AI-powered writing tools with AI Humanizer and Message AI feature being the latest addition, allowing users to generate, rewrite, refine, and humanize content without moving between separate platforms. The product is available via web platform, mobile apps on the App Store and Google Play, browser extensions for Chrome, Mozilla, and Edge, and a Google Docs add-on.

Vinet Kakadea, Founder of Kreativespace, said, “Kreativespace’s vision is to digitalize the entire Indian education ecosystem to support PM Modi’s Atmanirbhar Bharat scheme.”

About Kreativespace

Kreativespace with the Motto of Making Writing Accessible for Everyone: Kreativespace is an AI-powered writing platform built to make AI writing tools accessible, affordable, and effective for students, researchers, educators, professionals, content creators, startups, and enterprises. Founded by Vinet Kakadea, the company is incubated at IIT Kharagpur and has been recognized by AWS Startup Program, the NVIDIA Inception Program, and DPIIT under Startup India. For more information, visit kreativespace.com.

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/fulfilling-pm-modis-dream-of-atmanirbhar-bharat-indias-ai-writing-startup-kreativespace-incubated-at-iit-kharagpur-302804117.html

Continue Reading

News Wire

Santokbaa Humanitarian Award 2026 Marks 20 Years of Compassion and Service

SURAT, India, June 18, 2026 /PRNewswire/ — The Santokbaa Humanitarian Award 2026, instituted by Shree Ramkrishna Knowledge Foundation (SRKKF), the philanthropic arm of Shree Ramkrishna Exports (SRK), marked 20 years of honouring individuals who have made a lasting difference through compassion, service and leadership. The awards were presented recently in Surat.

This year’s Santokbaa Humanitarian Award was conferred on Padma Shri Dr. Gullapalli N. Rao, renowned Indian ophthalmologist and Founder-Chair of the LV Prasad Eye Institute, and Padma Shri Smt. Reema Nanavaty, development worker and Director of the Self-Employed Women’s Association (SEWA). Their work has touched millions of lives through healthcare, empowerment and community development.

In a significant addition this year, SRKKF introduced the Social Entrepreneur Award to recognise leaders who combine business excellence with measurable social impact. The inaugural award was presented to Shri Srikanth Bolla, Founder of Bollant Industries, a sustainable manufacturing company known for disability-inclusive employment and environmentally responsible practices.

The event was graced by Chief Guest Shri Harivansh Narayan Singh, Hon’ble Deputy Chairman of the Rajya Sabha and Guests of Honour Shri Harsh Sanghavi, Hon’ble Deputy Chief Minister of Gujarat; along with several other distinguished personalities.

Established in 2006 by Shri Govind Dholakia, Founder & Chairman Emeritus of Shree Ramkrishna Exports Pvt. Ltd. and SRKKF, the award reflects the legacy of compassion and selfless values embodied by his mother, Santokbaa. Over the past two decades, it has become a platform to honour individuals whose lives and work continue to inspire society.

The awardees are selected through a rigorous and transparent process led by an independent jury comprising leaders from diverse fields. The 2026 jury included Shri Govindan Rangarajan, Director, Indian Institute of Science (IISc), Bengaluru; Shri A.S. Kiran Kumar, Former Chairman, ISRO; Admiral R. Hari Kumar (Retd.), Former Chief of the Indian Navy; Shri Rishabh Shroff, Partner, Cyril Amarchand Mangaldas; and Shri Shreyans Dholakia, Entrepreneur and Brand Custodian, SRK.

Addressing the gathering, Chief Guest Shri Harivansh Narayan Singh said that the SRK Foundation is carrying forward Santokbaa’s legacy to the next generation by celebrating service, sacrifice and compassion over wealth or fame. He added that the family’s effort to connect this legacy with social entrepreneurship reflects the values of nation-building.

Shri Harsh Sanghavi said the Santokbaa Award reminds us that true achievement lies not only in personal success, but in bringing light and happiness to others. Shri Govind Dholakia said his mother Santokbaa spent her life guided by truth, love and compassion, and that her values continue to inspire the family’s work. He added that the award’s 20-year journey is a tribute to changemakers whose efforts have strengthened communities across the country.

Speaking on the honour, Dr. Gullapalli N. Rao said it was a privilege to receive the recognition on behalf of all those working to expand access to quality eye care. He said restoring sight restores dignity and opportunity, and praised SRK’s world-class operational systems. Smt. Reema Nanavaty said the award belonged to the millions of women whose resilience and entrepreneurial spirit continue to inspire SEWA’s mission. She noted that when women are empowered, they become agents of change for their families and communities. Shri Srikanth Bolla said his journey has shown that limitations often exist more in perception than reality, and that the award is a reminder that with the right support, every individual can contribute meaningfully to society.

Over the past 20 years, the Santokbaa Humanitarian Award has honoured 20 of India’s most distinguished humanitarian and social leaders, including Shri Ratan Tata, His Holiness the 14th Dalai Lama, Dr. Sudha Murty, Dr. Cyrus Poonawalla, Shri Shiv Nadar, Dr. Abhay Bang and Dr. Rani Bang, Dr. Verghese Kurien, Shri Kailash Satyarthi and Shri A.S. Kiran Kumar. With the introduction of the Social Entrepreneurship Award in 2026, the milestone celebration reaffirmed the importance of empathy, service and purposeful leadership in building a better future.

About Santokbaa Humanitarian Award:

Over the past 20 years, the Santokbaa Humanitarian Award has honoured 19 of India’s most distinguished humanitarian and social leaders, including Shri Ratan Tata, His Holiness the 14th Dalai Lama, Dr. Sudha Murty, Dr. Cyrus Poonawalla, Shri Shiv Nadar, Dr. Abhay Bang and Dr. Rani Bang, Dr. Verghese Kurien, Shri Kailash Satyarthi and Shri A.S. Kiran Kumar, among other eminent personalities. In 2026, SRKKF also instituted the Santokbaa Social Entrepreneurship Award, with Shri Srikanth Bolla becoming its inaugural recipient.

As the Santokbaa Humanitarian Award completed a remarkable 20-year journey, the milestone celebration reaffirmed the enduring importance of empathy, service and purposeful leadership in shaping a better future. The journey endures, contributing to nation-building through compassion, innovation and service to humanity.

For more information, visit: https://srk.foundation/honours

Photo: https://oyefilmy.com/wp-content/uploads/2026/06/santokbaa-humanitarian-award-2026-marks-20-years-of-compassion-and-service-1.jpg

 

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/santokbaa-humanitarian-award-2026-marks-20-years-of-compassion-and-service-302804299.html

Continue Reading

Trending